Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928870 | 0.82 | HSD11B1 (0.53) | EPHX2POLBCACNA1GCACNA1H | |
| SCHEMBL12932018 | 0.77 | NPC1 (0.94) | NPC1RAB9AEPHX2EPHX1FKBP1A | |
| SCHEMBL14342613 | 0.77 | POLB (0.47) | NPC1RAB9APOLBKMT2ACACNA1G | |
| SCHEMBL17117487 | 0.76 | POLB (0.61) | NPC1RAB9APOLBFKBP1ACACNA1G | |
| SCHEMBL7306852 | 0.76 | POLB (0.83) | NPC1RAB9APOLBFKBP1AMEN1 | |
| SCHEMBL26113012 | 0.75 | POLB (0.59) | NPC1RAB9APOLBCACNA1GCACNA1H | |
| SCHEMBL15310176 | 0.75 | NPC1 (1.00) | NPC1RAB9AEPHX2EPHX1MEN1 | |
| SCHEMBL26111732 | 0.75 | POLB (0.59) | NPC1RAB9APOLBCACNA1GCACNA1H | |
| SCHEMBL26107974 | 0.75 | POLB (0.59) | NPC1RAB9APOLBCACNA1GCACNA1H | |
| SCHEMBL8092824 | 0.74 | SIGMAR1 (0.59) | NPC1RAB9APOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | claimed |
| EP-2038255-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | High Point Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| EP-2038255-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | High Point Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HSD11B1, HSD3B1, CES1 | NPC1 531/4885RAB9A 2534/4885EPHX2 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.